<SEC-DOCUMENT>0001213900-25-034354.txt : 20250423
<SEC-HEADER>0001213900-25-034354.hdr.sgml : 20250423
<ACCEPTANCE-DATETIME>20250423083224
ACCESSION NUMBER:		0001213900-25-034354
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250423
FILED AS OF DATE:		20250423
DATE AS OF CHANGE:		20250423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		25859317

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0239144-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: April 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2025, Enlivex Therapeutics Ltd.,
a company organized under the laws of the State of Israel (&ldquo;Enlivex&rdquo;), issued a press release announcing that Enlivex will
present two poster abstracts at the Osteoarthritis Research Society International 2025 World Congress on Osteoarthritis, taking place
April 24-27, 2025, in Incheon (Seoul), South Korea. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K
and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="ea023914401ex99-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Press Release issued by Enlivex Therapeutics Ltd. on April 23, 2025.</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 23, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023914401ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON APRIL 23, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Enlivex Therapeutics to Showcase Allocetra&rsquo;s
Potential in Osteoarthritis at OARSI 2025 World Congress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Presentations to underscore Allocetra<SUP>TM</SUP>&rsquo;s
novel mechanism targeting immune imbalance in joint disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics
Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming immunotherapy company,&nbsp;today announced
that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 World Congress on Osteoarthritis,
taking place April 24-27, 2025, in Incheon (Seoul), South Korea.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;These presentations at OARSI 2025 will highlight the growing
body of evidence supporting Allocetra&rsquo;s<SUP>TM</SUP> potential as a novel therapeutic approach for osteoarthritis,&rdquo; said Oren
Hershkovitz, PhD, Chief Executive Officer of Enlivex. &ldquo;We believe that restoring macrophage homeostasis may address the underlying
drivers of chronic joint inflammation and cartilage degradation, potentially offering a promising new treatment pathway for millions of
patients worldwide.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The presentations will feature data from both preclinical and clinical
studies evaluating Allocetra&trade;, Enlivex&rsquo;s proprietary, off-the-shelf macrophage reprogramming cell therapy, in patients with
osteoarthritis. Allocetra&trade; is designed to reprogram macrophages into a homeostatic state, thereby promoting immune balance and resolving
chronic inflammation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Allocetra&trade; has demonstrated favorable safety and promising efficacy
signals in Phase I/II studies in moderate and end-stage osteoarthritis, including substantial and durable pain reduction, improved joint
function, and avoidance of knee replacement surgery. Preclinical studies have further supported its unique mechanism of action in modulating
macrophage-driven inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accepted Presentations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Flash Talk &amp; Poster Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title:</B> <I>Phase I/II Clinical Trial of Allocetra&trade; Cell Therapy for Knee Osteoarthritis: Initial Evidence of Response
to Inflammation Modulation</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Abstract Publication Number:</B> 092</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Flash Talk Session:</B> <I>Pain Mechanisms and Neuroinflammation in OA</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date &amp; Time:</B> April 26, 2025 | 11:31 &ndash; 11:33 AM KST</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Poster Sessions:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Friday, April 25 | 4:15 &ndash; 5:00 PM KST</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Saturday, April 26 | 4:15 &ndash; 5:00 PM KST</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Poster Number:</B> 092</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Poster Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Title:</B> <I>Biological Activity Characterization of Allocetra&trade;, a Novel Macrophage Reprogramming Cell Therapy, in Osteoarthritis
Preclinical Models</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Abstract Control ID:</B> 4231304</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Poster Sessions:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Friday, April 25 | 3:30 &ndash; 4:15 PM KST</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Saturday, April 26 | 3:30 &ndash; 4:15 PM KST</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>Poster Number:</B> 665</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Oren Hershkovitz, CEO and Einat Galamidi, MD, CMO, will attend
the conference and be available for meetings with stakeholders and members of the scientific community.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ENLIVEX</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Enlivex is a clinical stage macrophage reprogramming immunotherapy
company developing Allocetra&trade;, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic
state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of
life-threatening and life debilitating conditions. For more information, visit&nbsp;http://www.enlivex.com.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Safe Harbor Statement:&nbsp; This press release contains forward-looking
statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo;, &ldquo;could,&rdquo;
&ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo; and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRA&nbsp;<SUP>TM&nbsp;</SUP>programs. All such forward-looking
statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&nbsp; Investors are
cautioned that forward-looking statements involve risks and uncertainties that may affect&nbsp;Enlivex&rsquo;s&nbsp;business and prospects,
including the risks that&nbsp;Enlivex&nbsp;may not succeed in generating any revenues or developing any commercial products; that the
products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support
the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue
to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth
in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results
of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed,
later-stage trials. The development of any products using the ALLOCETRA&nbsp;<SUP>TM&nbsp;</SUP>product line could also be affected by&nbsp;a
number of&nbsp;other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses
and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of
patents and other proprietary rights held by competitors and other third parties.&nbsp; In addition to the risk factors described above,
investors should consider the economic, competitive, governmental,&nbsp;technological&nbsp;and other factors discussed in&nbsp;Enlivex&rsquo;s&nbsp;filings
with the Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Securities
and Exchange Commission.&nbsp; The forward-looking statements contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact:</B><BR>
Dave Gentry, CEO<BR>
RedChip Companies, Inc.<BR>
1-407-644-4256<BR>
ENLV@redchip.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J )8# 2(  A$! Q$!_\0
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MEFSB+S:_62X\1Z5XO_X*_P#P;\3^'KY-4T'6_P!@SQ)KFFZA:S+)97^E:O\
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MJKX616V@>$K :GXDO]$\+>&=4M(M*T'24YU'4GCLH0EA&=\WE. =XKW?0O\
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M%+&2DL<L4B2(Z$JZGAN2!^)G_!4;PPWP8^,?[.G[<-A '\.^&=1;X#?'D*A
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M0B.V2ZU,&&1(U?S2KKGZMTWQWX!U:PM=4TOXB^ ]1L+L"\M;O3/%_A^]T_&
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EO*M4E)WE*<I2;ZN3;;^]G]-X;*,+2P]&G"*Y84X);](KL['_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
